GB 501
Alternative Names: GB-501Latest Information Update: 22 Mar 2023
Price :
$50 *
At a glance
- Originator RainBio
- Developer CalciMedica
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; IDUA protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Corneal disorders
Most Recent Events
- 20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
- 11 Aug 2022 Suspended - Preclinical for Corneal disorders in USA due to cost-containment measures (Intraocular)
- 10 May 2022 Graybug plans a phase I/IIa trial in Corneal disorders in USA (Intraocular) in the second quarter of 2023